| Literature DB >> 29276263 |
Abstract
Migraine is a common disorder affecting 12% of the U.S. POPULATION: Prophylaxis is recommended for patients who experience frequent migraines. Because current drugs used for prophylaxis are not 100% effective and cause adverse effects that affect compliance, new strategies have been studied to prevent headaches. One new pharmacologic strategy is to use an inhibitor of the calcitonin gene-related peptide (CGRP). As a class, the CGRP receptor inhibitors have reduced monthly migraine days and are well tolerated. This article will briefly review CGRP inhibitors in development.Entities:
Keywords: drug information; formulary management/P&T; investigational drugs; neurology
Year: 2017 PMID: 29276263 PMCID: PMC5735702 DOI: 10.1177/0018578717723005
Source DB: PubMed Journal: Hosp Pharm ISSN: 0018-5787